Orthofix International N.V. , a diversified, global medical device company, announced FDA and European CE Mark approvals for its next-generation...
Alopecia is associated with significant psychological burden. There is limited evidence on the use of psychological interventions in conditions of hair loss.
Brittany Craiglow discusses setting expectations and navigating emotions for young people with alopecia areata.
Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle.
Adults with severe alopecia areata (AA) who took Olumiant (baricitinib) achieved significant scalp, eyelash and eyebrow hair regrowth and nearly 75% of those who responded to Olumiant 4-mg achieved 90% scalp coverage at 52 weeks, Eli Lilly and Company and Incyte announced at the American Academy of Dermatology (AAD) Annual Meeting.
Alopecia areata (AA) is a chronic, immune-mediated disease characterized by acute or chronic non-scarring hair loss, with a heterogeneity in clinical manifestations ranging from patchy hair loss to complete scalp and body hair loss.
Dignitana, a world leader in medical scalp-cooling technology, announced that the FDA has granted the company’s de novo application to...
Extending phase III BRAVE-AA1 and BRAVE-AA2 trials, a new 52-week pooled analysis shows that adults with severe alopecia areata (AA) who took Olumiant (baricitinib), from Eli Lilly, achieved significant scalp, eyelash and eyebrow hair regrowth and nearly 75% of those who responded to Olumiant 4-mg achieved 90% scalp coverage at 52 weeks.
Alopecia areata is an autoimmune disease that results in non-scarring hair loss, and it is clinically characterised by small patches of baldness on the scalp and/or around the body.